Approximately one thousand doses of Gilead Sciences' HIV prevention drug, lenacapavir, were delivered to Zambia and Eswatini. This delivery initiates a United States program to supply the long-acting drug to regions with high HIV prevalence. A senior State Department official, Jeremy Lewin, clarified that U.S.-funded doses would not be provided to South Africa, despite its significant HIV burden, encouraging the nation to fund its own supply.
The U.S. State Department had previously announced a plan to make lenacapavir available at cost through initiatives like PEPFAR and the Global Fund. Gilead is currently seeking regulatory approvals for distribution in several other high-burden sub-Saharan African countries, including Rwanda, Tanzania, and Botswana. The company aims to reach millions of people over three years through these partnerships.
The U.S. State Department had previously announced a plan to make lenacapavir available at cost through initiatives like PEPFAR and the Global Fund. Gilead is currently seeking regulatory approvals for distribution in several other high-burden sub-Saharan African countries, including Rwanda, Tanzania, and Botswana. The company aims to reach millions of people over three years through these partnerships.
